Liver Failure Nursing Guide

Key Liver Functions

Metabolic & Storage

Glucose metabolism & glycogen storage/release
Lipid metabolism: cholesterol synthesis, lipoprotein assembly
Amino acid metabolism & urea cycle (detoxifies ammonia)
Drug & toxin detoxification (CYP450 enzymes)

Synthetic & Secretory

Albumin synthesis (main plasma oncotic protein)
Clotting factors: I, II, V, VII, IX, X, XI (all except VIII)
Bile production: fat digestion, bilirubin excretion
Thrombopoietin (regulates platelet production)

Clinical Pearl Because the liver synthesises albumin and clotting factors, their serum levels (low albumin, prolonged INR) are direct markers of synthetic liver function — more reliable than enzyme levels alone.

CLD Progression Stages

Hepatitis

Inflammation

Fibrosis

Scarring

Cirrhosis

Irreversible

Decompensation

Complications

Liver Failure

End-stage

Decompensation is marked by the first occurrence of ascites, variceal bleed, hepatic encephalopathy, or jaundice in a previously compensated cirrhotic patient.

Common Causes in GCC

Infectious / Metabolic

HBV — endemic in Middle East; vertical & horizontal transmission; vaccination programmes now universal
HCV — transmission via blood/procedures; DAAs now achieve >95% cure
NAFLD/NASH — highest burden in GCC; driven by obesity & T2DM epidemic; can progress silently to cirrhosis

Other Aetiology

Alcohol-related — less prevalent in Muslim-majority population but present in expat community; approach non-judgementally
Autoimmune hepatitis — female predominance; elevated IgG, ANA/SMA positive
Wilson's disease — copper overload; young patients; Kayser-Fleischer rings
Haemochromatosis — iron overload; ferritin elevated, transferrin saturation >45%

Acute Liver Failure (ALF) — Definition

ALF Criteria (all three must be present)

Coagulopathy: INR ≥ 1.5
Any degree of hepatic encephalopathy
No pre-existing chronic liver disease
Onset within <26 weeks of first symptoms

Time Classification

Hyperacute<7 days jaundice → HE

Acute7–28 days

Subacute4–26 weeks

Common Causes ALF

Paracetamol overdoseMost common in West

HBV flare / HDVCommon in GCC

Drug-induced (DILI)Herbal remedies

Wilson's diseaseYoung patients

Child-Pugh Score Calculator

Assesses severity of chronic liver disease. Each parameter scores 1–3 points. Total 5–15.

Bilirubin (μmol/L)

Albumin (g/L)

INR

Ascites

Encephalopathy

MELD Score Calculator

Model for End-Stage Liver Disease. Predicts 90-day mortality. Used globally for transplant list prioritisation. Range 6–40.

Formula: 3.78×ln(Bilirubin mg/dL) + 11.2×ln(INR) + 9.57×ln(Creatinine mg/dL) + 6.43

Bilirubin (mg/dL)

INR

Creatinine (mg/dL)

Hepatic Encephalopathy (HE) Grades

West Haven Criteria — based on altered consciousness, intellectual function and behaviour.

Grade 0 — Minimal / Covert HE

No clinically apparent changes. Detected only by psychometric testing (Number Connection Test, PHES). Normal examination but subtle cognitive impairment affecting driving ability.

Grade 1 — Mild

Mild confusion, shortened attention span, slowed mentation, impaired calculation. Reversed sleep-wake cycle (sleepy by day, awake at night). Subtle personality changes.

Grade 2 — Moderate

Moderate confusion, lethargy. Asterixis (liver flap / flapping tremor) — ask patient to dorsiflex hands with arms outstretched. Behavioural change, slurred speech, disorientation to time.

Grade 3 — Marked

Gross disorientation, semi-stuporous but rousable. Incoherent or absent speech. Bizarre behaviour. GCS impaired — careful monitoring required. Asterixis may not be elicitable.

Grade 4 — Coma

Unresponsive to verbal or painful stimuli. GCS ≤8. ICU-level care required. Airway protection — consider intubation. Cerebral oedema risk (especially in ALF).

TIPS Mnemonic — HE Precipitants

T — Toxins & medications (sedatives, opioids, benzodiazepines)

I — Infection (SBP, UTI, pneumonia, cellulitis)

P — Portal hypertension changes (GI bleed, constipation, large paracentesis)

S — Sedatives & renal failure (electrolytes: hyponatraemia, hypokalaemia, dehydration)

HE Management

Pharmacological

Lactulose 15–30 mL three times daily — titrate to 2–3 soft stools/day; enemas (300 mL in 700 mL water) in acute grade 3–4
Rifaximin 550 mg BD — for secondary prevention of recurrent HE (add to lactulose)
Zinc supplementation (often deficient in cirrhosis)
Treat precipitant aggressively (antibiotics for infection, stop offending drugs)

Non-Pharmacological

Protein — do NOT restrict: modern guidance recommends 1.2–1.5 g/kg/day; restriction worsens sarcopaenia and outcomes
BCAA (branched-chain amino acid) supplements if intolerant of protein
Avoid sedatives and benzodiazepines (if needed: oxazepam cautiously)
Treat constipation proactively
Re-orientate, fall prevention, safety monitoring

Ascites & SBP

Ascites Management

Sodium restriction ≤88 mmol/day (2 g salt)
Spironolactone 100 mg + furosemide 40 mg (stepwise titration); maintain 100:40 ratio
Large volume paracentesis (LVP) for refractory ascites: drain up to 5 L safely
Albumin infusion: 6–8 g per litre drained (if >5 L) — prevents post-paracentesis circulatory dysfunction
TIPS procedure for refractory ascites (risks: worsened HE)
Monitor serum Na: hyponatraemia <125 mmol/L — restrict fluids

SBP Diagnosis & Treatment

Diagnostic criteria: PMN (polymorphonuclear cells) >250/μL in ascitic fluid — even without symptoms
Symptoms: fever, abdominal pain/tenderness, worsening HE, renal deterioration
Treatment: cefotaxime 2 g IV every 8 hours × 5 days (or ceftriaxone)
Albumin co-administration: 1.5 g/kg on day 1, 1 g/kg on day 3 — prevents HRS in SBP
Secondary prophylaxis: norfloxacin 400 mg daily (or ciprofloxacin)
Repeat diagnostic tap at 48 hours to confirm response (PMN drop >25%)

Paracentesis tip: Always send ascitic fluid for cell count, culture (inoculate blood culture bottles at bedside), albumin (calculate SAAG = serum albumin − ascitic albumin; >11 g/L = portal hypertension aetiology).

Variceal Haemorrhage

Acute variceal bleed = medical emergency — mortality 15–20% per episode

Immediate Management

ABC: airway protection (consider intubation if grade 3–4 HE)
Large bore IV access ×2, crossmatch, activate MTP if massive bleed
Terlipressin 2 mg IV bolus 4-hourly (or octreotide 50 mcg bolus → 50 mcg/hr infusion)
IV PPI (pantoprazole infusion)
Prophylactic antibiotics: ceftriaxone 1 g daily × 5–7 days (reduces SBP, mortality)
Urgent OGD (within 12 hrs if haemodynamically stable; within 6 hrs if haemodynamically unstable)
Endoscopic variceal ligation (EVL) — treatment of choice

Salvage / Further Options

Sengstaken-Blakemore tube — balloon tamponade for refractory bleeding; temporary bridge (max 24 hrs); risk: oesophageal rupture, aspiration
Transjugular Intrahepatic Portosystemic Shunt (TIPS) — for ongoing/recurrent bleed
Secondary prophylaxis: propranolol/carvedilol + repeat EVL until eradication
Transfusion target Hb 70–80 g/L (restrictive strategy improves outcomes)
Avoid over-transfusion — increases portal pressure

Hepatorenal Syndrome (HRS) & Coagulopathy

HRS

Acute kidney injury in cirrhosis without other cause (exclude hypovolaemia, nephrotoxins, obstruction)
HRS-AKI (type 1): rapid rise in creatinine >50% in <2 weeks — poor prognosis
HRS-CKD (type 2): stable or slowly progressive — often with refractory ascites
Treatment: terlipressin 1–2 mg IV 4–6 hourly + albumin 20–40 g/day
Noradrenaline + albumin (alternative if terlipressin unavailable)
Discontinue diuretics, avoid nephrotoxins
Renal replacement therapy (bridge to transplant)

Coagulopathy Monitoring

INR: reflects hepatic clotting factor synthesis (II, VII, IX, X). Does not capture full haemostatic picture (thrombomodulin thrombin generation often preserved)
Fibrinogen: true marker of disseminated coagulopathy / DIC
Platelet count: thrombocytopaenia from hypersplenism and reduced thrombopoietin
Viscoelastic testing (TEG/ROTEM): better reflects overall haemostasis
Avoid FFP for procedure prophylaxis unless active bleeding — small benefit, risk of volume overload
Vitamin K 10 mg IV if nutritional deficiency suspected

Pruritus Management

Cholestatic pruritus can be severe and debilitating, significantly affecting quality of life. Use a stepwise approach.

Step	Agent	Dose	Notes
1st	Bile acid sequestrants: Cholestyramine	4 g 1–4×/day before meals	Take 4 hrs away from other medications; may worsen cholestasis if biliary obstruction
2nd	Rifampicin	150–300 mg BD	Monitor LFTs — hepatotoxic in ~5%; drug interactions (CYP450 inducer)
3rd	Naltrexone (opioid antagonist)	50 mg daily	Start low (12.5 mg) to avoid opioid withdrawal-like reaction; avoid in opioid-dependent
4th	Sertraline	75–100 mg daily	Limited evidence but useful in refractory cases; monitor Na in cirrhosis
Local	Emollients, calamine, menthol cream	As needed	Cool environment, loose cotton clothing, cut nails short

Drugs to Avoid / Use Cautiously

AVOID in Liver Failure

NSAIDs: precipitate HRS, worsen ascites (inhibit prostaglandins)
Aminoglycosides: nephrotoxic — high HRS risk; only use with TDM if no alternative
IV contrast: use with hydration + N-acetylcysteine if eGFR borderline
Sedatives / benzodiazepines: precipitate HE
Proton pump inhibitors: associated with increased SBP risk — use only if indicated
Beta-lactam antibiotics with Na load: can worsen ascites

DOSE ADJUST

Opioids: reduce dose by 50%, increase dosing interval; avoid morphine (metabolites accumulate); prefer fentanyl
Paracetamol: safe at 2 g/day maximum (preferred analgesia); avoid in ALF
Statins: generally stopped in decompensated cirrhosis (may restart in compensated)
Antifungals: fluconazole — monitor LFTs; reduce dose in severe impairment
Antibiotics: review local protocols for dosing adjustments in Child-Pugh C

Nutrition in Liver Disease

Modern Guidance: Do NOT restrict protein in HE Older practice of protein restriction is harmful — it worsens sarcopaenia and muscle loss, which are independent predictors of mortality in cirrhosis. Target 1.2–1.5 g/kg/day of protein.

Late evening snack (complex carbohydrate): reduces overnight fasting, improves nitrogen balance, reduces hypoglycaemia risk
Small frequent meals (5–6/day): reduces postprandial metabolic load
BCAA supplementation: useful if intolerant of standard protein or in refractory HE
NG feeding in grade 3–4 HE or intake <60% requirement for 3+ days
Vitamin supplementation: thiamine (B1), folate, zinc — commonly deficient
Sodium restriction ≤88 mmol/day (2 g salt): helps control ascites with diuretics
Fluid restriction only if sodium <125 mmol/L (avoid routine fluid restriction)

Transplant Eligibility & GCC Centres

Indications for Listing

MELD score ≥15 (standard threshold for waitlisting)
MELD ≥25 = high urgency; MELD ≥35 = very high 90-day mortality risk
Acute liver failure (any aetiology meeting Kings College criteria)
Hepatocellular carcinoma within Milan criteria (single ≤5cm or 2–3 lesions ≤3cm)
Refractory complications: recurrent SBP, refractory ascites, HRS not responding to treatment
Recurrent variceal bleeding despite endoscopic and pharmacological treatment

Absolute Contraindications

Active extrahepatic malignancy (except skin cancers)
Active untreated infection (including TB, HIV with uncontrolled viral load)
Severe cardiopulmonary disease (FEV1 <40%, severe pulmonary HTN)
Active alcohol use — most centres require ≥6 months abstinence with psychosocial support
Cholangiocarcinoma (except selected hilar CCA at specialised centres)
Non-compliance with medical treatment (assessed during evaluation)

GCC Transplant Centres

Saudi Arabia

King Faisal Specialist Hospital & Research Centre, Riyadh — largest programme in GCC; living and deceased donor

UAE

Sheikh Khalifa Medical City, Abu Dhabi; Dubai Hospital transplant programme. HAAD-regulated criteria.

Qatar

Hamad Medical Corporation, Doha. Expanding programme; international partnerships for complex cases.

Living Related Liver Donation (LRLD) in GCC LRLD is particularly common in GCC due to lower rates of deceased donation (cultural/religious considerations around brain death definitions vary). A living donor (usually first-degree relative) donates the right or left hepatic lobe. Donor evaluation is rigorous (volumetry, hepatic anatomy, liver biopsy) and donor safety is paramount.

Post-Operative Nursing Care (First 72 Hours)

Parameter	What to Monitor	Normal / Target	Action if Abnormal
Bile output (T-tube)	Colour, volume, consistency per shift	250–1000 mL/24hr; golden-green colour	Dark/reduced = bile leak or obstruction; report immediately
LFTs	ALT, AST, ALP, GGT, bilirubin daily	Trending downward by day 3–5	Sudden rise = rejection or ischaemia; biopsy needed
INR / Coagulation	INR, PT, fibrinogen BD initially	INR improving toward normal by day 3	Persistent high INR = poor graft function; alert transplant team
Renal function	Creatinine, urine output hourly	UO >0.5 mL/kg/hr; creatinine improving	Tacrolimus nephrotoxicity; calcineurin inhibitor dose reduction
Glucose	Hourly in ICU phase	5–10 mmol/L	Hypoglycaemia = poor graft function; hyperglycaemia = steroid effect / infection
Haemodynamic	MAP, HR, CVP, drain output	MAP >65, HR <100, drain <200 mL/hr	Haemorrhage = urgent surgical review; vasopressors if sepsis

Immunosuppression Regimen

Triple immunosuppression is standard: tacrolimus + mycophenolate mofetil (MMF) + prednisolone

Tacrolimus (Calcineurin Inhibitor)

Trough level target: 8–12 ng/mL (first year)
Gradually reduced: 5–8 ng/mL year 2–3; aim 3–5 ng/mL long-term
Nephrotoxic — monitor creatinine closely
Neurotoxic: tremor, headache, seizures (high levels)
Diabetogenic — new-onset diabetes post-transplant (NODAT) in up to 20%
Drug interactions: CYP3A4 — azoles, macrolides increase levels; rifampicin dramatically decreases levels
Grapefruit juice increases levels — advise patients to avoid

MMF & Prednisolone

MMF 500 mg–1 g BD: antimetabolite; SE: diarrhoea, nausea, leukopenia
Monitor FBC: withhold if WBC <2.0 or neutrophils <1.0
Prednisolone: high dose initially (20 mg/day); taper to 5 mg by 3 months; many protocols aim for steroid-free at 6–12 months
Steroid SEs: diabetes, hypertension, osteoporosis, mood changes, cushingoid features
Bone protection: calcium + vitamin D supplementation from day 1
Annual DEXA scan; bisphosphonate if osteoporotic T-score <-2.5

Rejection & Infectious Complications

Acute Cellular Rejection (ACR)

Peaks at 5–10 days post-transplant; can occur any time
Signs: fever, graft tenderness, rising bilirubin, elevated AST/ALT
Diagnosis: liver biopsy (Banff criteria: portal triaditis, bile duct inflammation, endotheliitis)
Treatment: IV methylprednisolone 500 mg–1 g daily × 3 days
Steroid-resistant: antithymocyte globulin (ATG) or dose-adjust tacrolimus
Hyperacute rejection (antibody-mediated): rare, requires plasmapheresis, rituximab

Infection Prophylaxis

CMV: valganciclovir prophylaxis 3–6 months (longer if D+/R−); monitor CMV PCR monthly
PCP (Pneumocystis jirovecii): co-trimoxazole 480 mg OD for 12 months
Fungal: fluconazole 400 mg OD for 1–3 months
TB: LTBI screening (IGRA/Mantoux) pre-transplant; treat LTBI before transplant with isoniazid
HBV prophylaxis: HBIG + tenofovir post-transplant in HBV recipients — lifelong in many protocols
Avoid live vaccines post-transplant; update all vaccines pre-transplant

Viral Hepatitis in the GCC

HBV

Intermediate-high endemicity historically across Middle East (HBsAg prevalence 2–5%)
Universal infant HBV vaccination now established in all GCC states — cohort protection growing
Screening recommended for all healthcare workers, pregnant women, dialysis patients
Complications: cirrhosis in 15–25% over 25 years; HCC risk (surveillance with USS + AFP every 6 months)
Treatment: tenofovir disoproxil fumarate (TDF) or entecavir first-line — lifelong in most cases

HCV — The Cure

HCV prevalence in GCC: 0.5–2% (Egypt/region historically higher)
Direct-acting antivirals (DAAs): ledipasvir/sofosbuvir, glecaprevir/pibrentasvir, elbasvir/grazoprevir
Sustained virological response (SVR) = cure: >95% with 8–12 week courses
All patients with confirmed HCV should be treated (including cirrhosis — can improve Child-Pugh class)
Post-SVR: continue HCC surveillance if cirrhosis (does not disappear with cure)
No vaccine available — harm reduction (needlestick, sexual transmission counselling)

NAFLD Epidemic & GCC

NAFLD is now the leading cause of chronic liver disease in GCC countries GCC nations have among the highest global rates of obesity (35–45% in some countries) and T2DM (prevalence up to 17–23%). NAFLD prevalence estimated 30–40% in general GCC adult population.

NAFLD → NASH Progression

NAFLD: steatosis alone — benign; NASH: steatosis + inflammation + ballooning — risk of fibrosis progression
Metabolic risk factors: obesity, T2DM, hypertension, dyslipidaemia (metabolic syndrome)
Diagnosis: USS (steatosis), elastography (FibroScan for fibrosis), biopsy for definitive NASH grading
Progression: 1–3% develop cirrhosis/year from NASH; NASH-cirrhosis = 2nd most common transplant indication globally

Lifestyle Interventions

Weight loss target: 7–10% body weight achieves histological improvement in NASH
>10% weight loss: some evidence of fibrosis regression
Mediterranean diet: olive oil, fish, vegetables, nuts — reduces liver fat
Exercise: aerobic (150 min/week moderate intensity) + resistance training
No approved pharmacotherapy for NASH fibrosis yet (resmetirom approved 2024 in USA for MASH with F2–F3 fibrosis)
Optimise diabetes and lipid management (GLP-1 agonists: semaglutide promising)
Avoid herbal weight loss supplements — common cause of DILI in GCC

Ramadan & Liver Disease

Islamic scholarship permits exemption from fasting for those with serious illness Patients with decompensated cirrhosis, acute liver failure, or those on complex medication regimens should be counselled pre-Ramadan. Involve the patient's religious beliefs sensitively.

Risks During Fasting

Hypoglycaemia: liver's reduced glycogen reserve and gluconeogenesis capacity; blood glucose monitoring essential
Constipation: reduced fluid and food intake; constipation precipitates HE — lactulose timing adjustment critical
Dehydration: in hot GCC climate; diuretics may worsen hypovolaemia → precipitate HRS
Medication timing disruption: tacrolimus must maintain 12-hourly intervals (transplant patients)
Reduced compliance with medications missed during daylight hours

Nursing Guidance

Pre-Ramadan assessment: formal review of clinical status, MELD, recent complications
Advise fasting ONLY in compensated cirrhosis (Child-Pugh A) with stable disease
Recommend against fasting in: Child-Pugh B/C, recent variceal bleed, active HE, HRS, severe ascites
Medication timing plan: document revised schedule for Suhoor and Iftar administration
Educate on warning signs: confusion, severe fatigue, significant abdominal distension — break fast immediately

Cultural Sensitivity in GCC Practice

Non-judgemental approach to alcohol-related liver disease: significant stigma in Muslim-majority settings; patients may conceal alcohol use; use CAGE or AUDIT tool sensitively in private; document as "alcohol-related" factually without moral commentary
Family-centred communication: in GCC cultures, family members are often central to medical decision-making; involve with patient's explicit consent; maintain patient confidentiality (especially regarding alcohol or other stigmatised causes)
Modesty considerations: abdominal examination, paracentesis — ensure same-gender healthcare provider where possible or appropriate draping; explain procedure in patient's preferred language
End-of-life discussions: liver failure can be terminal; culturally sensitive palliative care discussions; involve Islamic chaplaincy services; Durable DNR discussions require careful family engagement
Language barriers: use certified medical interpreters (not family members) for breaking bad news or obtaining informed consent

Quick Reference Cards

HE Grades at a Glance

Grade 0Psychometric only

Grade 1Mild confusion, sleep reversal

Grade 2Asterixis, moderate confusion

Grade 3Stuporous, incoherent

Grade 4Coma, GCS ≤8

Child-Pugh Classes

Class A (5–6 pts)Well compensated — 1yr survival 100%

Class B (7–9 pts)Significant dysfunction — 80%

Class C (10–15 pts)Decompensated — 45%

MELD Score Mortality

MELD <101.9% mortality

MELD 10–196% mortality

MELD 20–2919.6% mortality

MELD 30–3952.6% mortality

MELD ≥4071.3% mortality

SBP Criteria

PMN threshold>250 cells/μL

1st-line antibioticCefotaxime 2g IV q8h

Albumin Day 11.5 g/kg IV

Albumin Day 31 g/kg IV

Duration5 days

MCQ Quiz — Liver Disease Nursing

10 questions. Select your answers then click Submit to see your score and explanations.

QUESTION 1 OF 10

A Child-Pugh score of 9 classifies the patient as which class?

Child-Pugh Class A = 5–6 points, Class B = 7–9 points, Class C = 10–15 points. A score of 9 falls in Class B.

QUESTION 2 OF 10

A cirrhotic patient develops asterixis (flapping tremor) and moderate confusion. Which grade of hepatic encephalopathy is this?

Grade 2 HE is characterised by moderate confusion, asterixis (flapping tremor), and behavioural change. Grade 1 is mild/subtle; Grade 3 is semi-stuporous; Grade 4 is coma.

QUESTION 3 OF 10

What is the diagnostic PMN threshold in ascitic fluid for Spontaneous Bacterial Peritonitis (SBP)?

SBP is diagnosed when ascitic fluid PMN (polymorphonuclear cell) count is >250 cells/μL, even in the absence of symptoms or positive culture.

QUESTION 4 OF 10

What is the correct lactulose administration target for managing hepatic encephalopathy?

Lactulose is titrated to achieve 2–3 soft stools per day. This reduces intestinal ammonia production and absorption. Too few stools means under-dosing; too many (diarrhoea) risks dehydration and electrolyte imbalance, which can worsen HE.

QUESTION 5 OF 10

After a large volume paracentesis of 6 litres, what albumin infusion is recommended to prevent post-paracentesis circulatory dysfunction?

Guidelines recommend 6–8 g of 20% human albumin solution per litre of ascites drained, particularly when >5 litres are removed. This prevents the haemodynamic consequences of rapid fluid shifts (PPCD).

QUESTION 6 OF 10

What is the recommended daily protein intake for a cirrhotic patient with hepatic encephalopathy?

Modern guidelines recommend 1.2–1.5 g/kg/day of protein even in HE. Protein restriction worsens sarcopaenia, which is an independent predictor of mortality in cirrhosis. The old practice of protein restriction is now considered harmful.

QUESTION 7 OF 10

What is the therapeutic tacrolimus trough level target in the first year after liver transplantation?

Standard tacrolimus trough levels are 8–12 ng/mL in the first year post-transplant. Levels that are too low risk rejection; levels that are too high cause nephrotoxicity, neurotoxicity and infection risk.

QUESTION 8 OF 10

Which drug combination is used as first-line treatment for Hepatorenal Syndrome (HRS)?

Terlipressin (vasopressin analogue causing splanchnic vasoconstriction) combined with human albumin is the evidence-based first-line treatment for HRS-AKI. NSAIDs are absolutely contraindicated in cirrhosis as they precipitate HRS.

QUESTION 9 OF 10

A patient with cirrhosis develops a fever and their ascitic fluid shows PMN 320 cells/μL. What is the first-line antibiotic and what co-intervention reduces mortality?

SBP (PMN >250) is treated with IV cefotaxime 2 g every 8 hours for 5 days. Albumin infusion (1.5 g/kg on day 1, 1 g/kg on day 3) significantly reduces mortality by preventing HRS development.

QUESTION 10 OF 10

In the GCC context, which liver disease is currently the most prevalent and linked to the regional epidemic of obesity and Type 2 diabetes?

NAFLD is now the leading cause of chronic liver disease in GCC countries, driven by high rates of obesity and T2DM. GCC nations have some of the world's highest prevalence of metabolic syndrome, making NAFLD/NASH the dominant hepatological challenge in the region.